Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Profiting From The Takeda Pharmaceutical and Shire PLC Deal

We initiated a long position in shares of Shire PLC (LON: SHP) (1% exposure) and Takeda Pharmaceutical Co Ltd (TYO: 4502) (2% exposure) following the announcement that Japan’s Takeda will acquire the UK’s Shire.

The key rationale is to capture a very attractive deal spread of approximately 15% in absolute returns upon deal completion, and a potential sharp re-rate in the shares of Takeda.

The perceived uncertainty and consecutive deal re-negotiation were key factors that have heavily weighed on the share price of Takeda, as well as fears over a large capital raising to fund the deal.

In addition, some big M&A investors setup the M&A spread by going long SHP and short Takeda, further impacting the Takeda share price.

Rationale:

What Happens If The Deal Falls Through?

The market currently prices a 55% probability of deal completion for Shire (“SHP”), due to the vote risk at Takeda’s upcoming shareholder meeting. If the SHP deal fails, we believe SHP will trade approximately 15% lower. However, this is not the first time that SHP has shopped around, and we believe there could be other counterbidders emerging.

In addition, if the acquisition ultimately falls through, it could be an opportunity for the Takeda shares to make up lost ground in excess of 20% since the acquisition proposal was first announced. This would result in a net gain for our investments.

And If The Deal Goes Ahead?

Conversely, if the acquisition with SHP completes, not only would we capture the current attractive M&A deal spread but also an upside re-rate in Takeda shares.

The substantial cash flow generation expected to result from the acquisition will enable the combined group to de-lever quickly from around five times net debt/EBITDA (earnings before interest, taxes, depreciation and amortization) following completion of the deal. Takeda intends to maintain its investment grade credit rating with a target net debt /EBITDA of two times in the next 5 years.

With the SHP deal, Takeda Pharma’s core earnings per share would be highly accretive, particularly in the outer years, in excess of 70%.

From a strategic fit perspective, SHP would add to two of Takeda’s three core competencies, gastroenterology, and neuroscience, whilst from a pipeline perspective it complements the pipeline of early and late-stage programs.

Takeda Pharma’s FY19 expected core P/E is 12.2 times, which marks it a discount to the FY19 expected consensus of 13.3 times for the major global pharma companies.

In view of limited downside risk, due to the Company’s current dividend yield of 4.1%, we see the stock’s risk-return profile appealing and skewed to the upside from current depressed levels.

This analysis was contributed by Antonio Meroni, Senior Fund Manager for the Pengana Absolute Return Asia Pacific FundSubscribe to Pengana’s quarterly Insights for all their latest stock stories.

 

This article contains general information only and is issued by Pengana Investment Management Limited, AFSL: 219 462 The information does not take into account your needs, goals or objectives. Therefore, you should speak to a qualified financial adviser before acting on the information. 

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content